Clinical Trial Update: Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing blood levels of ReFacto and Advante in Hemophilia A was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Advante
• Refacto (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 4 | Status: WITHDRAWN